Aytu BioPharma (AYTU) 8-K Other Events

Exhibit 99.1

Aytu BioScience, Inc.

Proforma Balance Sheet

June 30, 2017

Unaudited

	6/30/2017			Pro Forma		Pro Forma
	Consolidated			Adjustments (a)		Combined (b)
Assets
Current assets
Cash and cash equivalents	$	802,328		$	10,637,752	$	11,440,080
Restricted cash		75,214					75,214
Accounts receivable, net		528,039			-		528,039
Inventory, net		1,312,221			-		1,312,221
Prepaid expenses and other		310,760			-		310,760
Total current assets		3,028,562			10,637,752		13,666,314
Fixed assets, net		647,254			-		647,254
Developed technology, net		1,337,333			-		1,337,333
Customer contracts, net		77,667			-		77,667
Trade names, net		164,037			-		164,037
Natesto asset		9,231,072			-		9,231,072
Goodwill		238,426			-		238,426
Patents, net		271,278			-		271,278
Deposits		2,888			-		2,888
Total long-term assets		11,969,955			-		11,969,955
Total assets	$	14,998,517		$	10,637,752	$	25,636,269
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and other	$	2,220,400		$	-	$	2,220,400
Accrued liabilities		782,536			-		782,536
Accrued compensation		339,704			-		339,704
Deferred rent		6,673			-		6,673
Contingent consideration		261,155			-		261,155
Warrant derivative liability		-			3,323,411		3,323,411
Total current liabilities		3,610,468			3,323,411		6,933,879
Contingent consideration		7,386,782			-		7,386,782
Deferred rent		1,451			-		1,451
Total liabilities		10,998,701			3,323,411		14,322,112
Commitments and contingencies
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued		-			1		1
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued
and outstanding 824,831 in 2017 and 187,098 in 2016		82			320		402
Additional paid-in capital		73,069,463			7,314,020		80,383,483
Accumulated deficit		(69,069,729	)		-		(69,069,729	)
Total stockholders' equity		3,999,816			7,314,341		11,314,157
							-
Total liabilities and stockholders' equity	$	14,998,517		$	10,637,752	$	25,636,269

(a) These are the adjustments to account for the $11.8M financing transaction on 8/15/17

(b) This is the proforma Balance sheet as if the $11.8M financing had happened on 6/30/17